KR20230120141A - Covid-19를 치료하기 위한 dsg2 조성물 및 방법 - Google Patents

Covid-19를 치료하기 위한 dsg2 조성물 및 방법 Download PDF

Info

Publication number
KR20230120141A
KR20230120141A KR1020237024240A KR20237024240A KR20230120141A KR 20230120141 A KR20230120141 A KR 20230120141A KR 1020237024240 A KR1020237024240 A KR 1020237024240A KR 20237024240 A KR20237024240 A KR 20237024240A KR 20230120141 A KR20230120141 A KR 20230120141A
Authority
KR
South Korea
Prior art keywords
dsg2
ser
val
pro
thr
Prior art date
Application number
KR1020237024240A
Other languages
English (en)
Korean (ko)
Inventor
쉬인 푸
리안 에드워드 타일러
Original Assignee
아르바다 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르바다 테라퓨틱스 인코포레이티드 filed Critical 아르바다 테라퓨틱스 인코포레이티드
Publication of KR20230120141A publication Critical patent/KR20230120141A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237024240A 2020-12-15 2021-12-15 Covid-19를 치료하기 위한 dsg2 조성물 및 방법 KR20230120141A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US63/125,583 2020-12-15
US202163274715P 2021-11-02 2021-11-02
US63/274,715 2021-11-02
PCT/US2021/063433 WO2022132854A1 (fr) 2020-12-15 2021-12-15 Compositions de dsg2 et procédés pour le traitement de la covid-19

Publications (1)

Publication Number Publication Date
KR20230120141A true KR20230120141A (ko) 2023-08-16

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024240A KR20230120141A (ko) 2020-12-15 2021-12-15 Covid-19를 치료하기 위한 dsg2 조성물 및 방법

Country Status (9)

Country Link
EP (1) EP4263588A1 (fr)
JP (1) JP2024500250A (fr)
KR (1) KR20230120141A (fr)
AU (1) AU2021400845A1 (fr)
CA (1) CA3202364A1 (fr)
IL (1) IL303444A (fr)
MX (1) MX2023006704A (fr)
TW (1) TW202237634A (fr)
WO (1) WO2022132854A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081674A1 (fr) * 2021-11-02 2023-05-11 Arvada Therapeutics, Inc. Compositions dsg2 et méthodes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments

Also Published As

Publication number Publication date
WO2022132854A1 (fr) 2022-06-23
AU2021400845A1 (en) 2023-07-13
TW202237634A (zh) 2022-10-01
JP2024500250A (ja) 2024-01-05
IL303444A (en) 2023-08-01
MX2023006704A (es) 2023-06-20
EP4263588A1 (fr) 2023-10-25
CA3202364A1 (fr) 2022-06-23

Similar Documents

Publication Publication Date Title
US5270199A (en) Human mannose-binding protein
US20180112193A1 (en) Csf1 therapeutics
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
EA005005B1 (ru) ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO1989001519A1 (fr) Proteine humaine liant le mannose
JP2019206548A (ja) 膵炎を治療するための薬剤の製造におけるil−22二量体の使用
CN109328069B (zh) Il-22在治疗坏死性小肠结肠炎中的用途
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
KR20230120141A (ko) Covid-19를 치료하기 위한 dsg2 조성물 및 방법
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
TW202143996A (zh) 使用可溶性cd24治療病毒性肺炎之方法
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US20240279304A1 (en) Dsg2 compositions and methods
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
JP6416480B2 (ja) 関節リウマチまたはその関連疾患の予防または治療剤
JP2024540220A (ja) Dsg2組成物及び方法
US20240299505A1 (en) Composition for improving, preventing or treating inflammatory bowel disease comprising nampt-derived peptide as active ingredient
US20230139938A1 (en) Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition
WO2022020544A1 (fr) Méthode de traitement d'une affection inflammatoire
EP4386011A1 (fr) Protéine de fusion d'interféron alpha d'anticorps ciblant gpc3 et son utilisation
JPH07508733A (ja) 白血病抑制因子結合蛋白
AU2426288A (en) Human mannose binding protein